EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series

Chloé Pannecoucke, Nadia Valin iD, Gilles Peytavin, Sidonie Lambert, Laurence Morand Joubert, Djeneba Fofana, Estelle Nerozzi Banfi, Emma Torres, Jean-Luc Meynard, Yasmine Abi Aad, Thibault Chiarabini iD, Karine Lacombe

Antiviral Therapy · 2026-06 · 31 (3)

DOI: 10.1177/13596535261436877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Therapy, online erschienen am 13.05.2026. Verfasst von Chloé Pannecoucke und 11 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, GH Sorbonne.Université, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective was to evaluate the safety, pharmacokinetics and efficacy of an alternative deltoid site for CAR-LA.

Design

This is a prospective cohort of people living with HIV (PLWHIV) switching for intramuscular long acting cabotegravir and rilpivirine (CAR-LA).

Methods

Clinical and biological data were collected at baseline, month 1 (M1), month 3 (M3), and every three months thereafter, when available.

Results

A total of 15 patients were enrolled between August 2022 and October 2024. Of these, 11 were transgender women, 1 cisgender woman, and 3 cisgender males. The median duration of plasma HIV-1-RNA (pVL)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsAnti-HIV AgentsPyridonesHumansFemaleMaleInjections, IntramuscularAdultProspective StudiesHIV-1Treatment OutcomeDiketopiperazinesMiddle AgedDeltoid Muscle

Stichwörter der Autor:innen

HIVcabotegravirlong actingrilpivirinetolerance

Substanzen

RilpivirinecabotegravirAnti-HIV AgentsPyridonesDiketopiperazines

Autor:innen und Institutionen

  • AP-HP, GH Sorbonne.Université, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France.
  • APHP.Nord, Bichat-Claude Bernard Hospital, Pharmacology Department, Paris, France.
  • UMR1137, IAME, Inserm, Paris, France.
  • Santé Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique APHP, Hôpital Saint-Antoine, Département de Virologie, Paris, France.
  • Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris, France.

ORCID-Profile: Nadia Valin, Thibault Chiarabini

Zitieren

APA

Pannecoucke, C., Valin, N., Peytavin, G., Lambert, S., Morand Joubert, L., Fofana, D., Nerozzi Banfi, E., Torres, E., Meynard, J. L., Abi Aad, Y., Chiarabini, T., & Lacombe, K. (2026). Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series. Antiviral Therapy, 31(3). https://doi.org/10.1177/13596535261436877

Vancouver

Pannecoucke C, Valin N, Peytavin G, Lambert S, Morand Joubert L, Fofana D, et al. Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series. Antiviral Therapy. 2026;31(3). doi:10.1177/13596535261436877

BibTeX
@article{Pannecoucke2026,
  author = {Pannecoucke, Chloé and Valin, Nadia and Peytavin, Gilles and Lambert, Sidonie and Morand Joubert, Laurence and Fofana, Djeneba and Nerozzi Banfi, Estelle and Torres, Emma and Meynard, Jean-Luc and Abi Aad, Yasmine and Chiarabini, Thibault and Lacombe, Karine},
  title = {Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series},
  journal = {Antiviral Therapy},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1177/13596535261436877}
}
Kostenlos starten →